Angiotensin receptor blocker/Calcium antagonist combination therapy on diurnal blood pressure variatio
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000013050
- Lead Sponsor
- Jichi Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who meet one of the following criteria are excluded: 1)Secondary hypertension 2)Congestive heart failure; onset of acute myocardial infarction in the past 6 month; onset of cerebrovascular disturbance in the past 6 month; current atrial fibrillation or atrioventricular block or severe arrhythmia. 3)hepatic insufficiency (AST or ALT >X2 the upper limit of the normal range) , renal insufficiency (serum Crl.>1.5mg/dL) 4)Diabetic patients being treated with aliskiren. 5)Allergy or drug hypersensitivity. 6)Lack of the informed consent for any reason (e.g. dementia). 7)Women suspected of being pregnant. 8)Patients being ineligible by the attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Target blood pressure reduction rate (clinic blood pressure less than 140/90 mm Hg ). - To document the proportion of extreme-dipper, dipper, non-dipper and riser (diurnal blood pressure variation).
- Secondary Outcome Measures
Name Time Method - Target blood pressure achievement rate and blood pressure lowering level at the final assessment. - Change in serum creatinine level (e-GFR) and microalbumin level. *eGFR(mL/min/1.73m2) = 194 X Cr -1.094 X age -0.287 X Cr -1.154 (X 0.739 for women) - Change in highly sensitive cardiac troponin T (hs-cTnT), NT-proBNP.